Celltrion launches Remsima IV liquid formulation in Europe, securing tenders in Denmark and Norway and planning further EU launches.
This launch strengthens Celltrion’s competitive position in the European biosimilar market by offering a more efficient formulation, potentially accelerating adoption and reducing healthcare costs. It also signals Celltrion’s expanding footprint in key EU countries.
Remsima IV liquid formulation launched in Europe, targeting multiple EU markets.
Secured national tenders in Denmark and Norway, with further launches planned in France, Netherlands, and Czech Republic.
Liquid formulation reduces drug preparation time and costs by approximately 50%.
Secured national tenders in Denmark and Norway, with further launches planned in France, Netherlands, and Czech Republic.
Remsima IV liquid formulation launched in Europe, targeting multiple EU markets.
Sign in to save notes on signals.
Sign In